Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 50 of 872

TitleReference numberPublishedLast updated
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphomaTA1113
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1114
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Delgocitinib for treating moderate to severe chronic hand eczemaTA1107
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TA1102
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Sparsentan for treating primary IgA nephropathyTA1074
Targeted-release budesonide for treating primary IgA nephropathyTA937
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitableTA1097
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitisTA1096
Tirzepatide for managing overweight and obesityTA1026
Tirzepatide for treating type 2 diabetesTA924
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and overTA1093
Guselkumab for treating moderately to severely active ulcerative colitisTA1094
Guselkumab for previously treated moderately to severely active Crohn's diseaseTA1095
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancerTA1092
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsTA1091
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinomaTA1090
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1088
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)TA1089
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrenceTA1086
Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollenTA1087
Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and overTA1085
Cenobamate for treating focal onset seizures in epilepsyTA753
Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)TA1082
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)TA1083
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)TA1084
Fruquintinib for previously treated metastatic colorectal cancerTA1079
Mirikizumab for previously treated moderately to severely active Crohn's diseaseTA1080
Zanubrutinib for treating relapsed or refractory mantle cell lymphomaTA1081
Dapagliflozin for treating chronic kidney diseaseTA1075
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA1077
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal)TA1078
Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesTA1073
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072
Spesolimab for treating generalised pustular psoriasis flaresTA1070
Linzagolix for treating symptoms of endometriosisTA1067

Results per page

  1. 10
  2. 25
  3. 50
  4. All